JOHN NGUYEN: Open Payments
NPI 1558924803 · REDDING, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,027 in 62 payments from 14 companies in 2025. Trend: 2023 $1,746 · 2024 $2,561 · 2025 $2,027
Food & beverage: $2,027
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $361 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $268 |
| Janssen Pharmaceuticals, Inc | 4 | $205 |
| Vanda Pharmaceuticals Inc. | 3 | $196 |
| ABBVIE INC. | 10 | $185 |
| Collegium Pharmaceutical, Inc. | 2 | $144 |
| Teva Pharmaceuticals USA, Inc. | 1 | $118 |
| Neurocrine BioSciences, Inc. | 5 | $117 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
Products named: CAPLYTA, ARISTADA, INVEGA SUSTENNA, VRAYLAR, FANAPT, Jornay PM, LYBALVI, REXULTI.
Industry payments across CA — which companies pay providers there.
